Waystar Holding Corp. (WAY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Waystar's earnings call highlights strong revenue and EBITDA guidance, cost synergies from Iodine acquisition, and strategic AI advancements. The Q&A section reveals positive analyst sentiment, with interest in AI-driven growth and platform adoption. Despite unclear responses on competitive ROI and pricing strategies, the overall sentiment remains positive due to raised guidance, AI opportunities, and platform preference. The lack of market cap data suggests a moderate positive reaction, aligning with the 'Positive' category (2% to 8%).
Key Financial Performance
Q4 Revenue $304 million, growing 24% year-over-year and 12% organically. Reasons for growth include the mission-critical nature of the platform, elevated patient utilization, and successful onboarding of new clients.
Full Year Revenue $1.1 billion, increased 17% year-over-year. Organic revenue increased 13%. Growth attributed to strong client retention and expansion, healthy patient utilization, and new client implementations.
Adjusted EBITDA (Q4) $129 million, up 29% year-over-year with an adjusted EBITDA margin of 42.5%. Growth driven by efficient operations and realization of acquisition cost synergies.
Adjusted EBITDA (Full Year) $462 million, up 21% year-over-year with a 42% margin. Growth attributed to disciplined platform expansion and operational efficiency.
Subscription Revenue (Q4) $168 million, increased 38% year-over-year and 25% sequentially. Growth driven by rapid time to revenue and strong client retention.
Volume-Based Revenue (Q4) $134 million, increased 11% year-over-year and 1% sequentially. Growth supported by steady double-digit growth from provider solution transactions and patient payment dollars.
Unlevered Free Cash Flow (Q4) $80 million, converted 79% of adjusted EBITDA to unlevered free cash flow. Growth supported by sustained deleveraging.
Unlevered Free Cash Flow (Full Year) $365 million, converted 79% of adjusted EBITDA to unlevered free cash flow. Growth supported by sustained deleveraging.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue milestone: Waystar crossed $1 billion in revenue for 2025, exceeding revenue and EBITDA guidance.
AI advancements: Waystar AltitudeAI prevented over $15 billion in denials, reduced appeal time by 90%, and increased denial overturn rates.
New AI capabilities: Launched agentic capabilities that cut documentation analysis by 40%.
Acquisition of Iodine Software: Added over 1,000 hospitals and health systems, expanding addressable market and clinical intelligence.
Client growth: Added 85 clients with trailing 12-month spend above $100,000, up from 30 a year ago.
Cross-sell and upsell: Achieved significant cross-sell and upsell momentum, with 112% net revenue retention and 97% gross revenue retention.
Revenue growth: Q4 revenue reached $304 million, growing 24% year-over-year and 12% organically.
Adjusted EBITDA: Achieved $129 million in Q4 adjusted EBITDA with a 42.5% margin, exceeding long-term target of 40%.
Integration of Iodine: Integration ahead of plan, with over 90% of cost synergies expected to be realized in fiscal 2026.
AI-driven automation: Focused on autonomous revenue cycle with AI agents acting on behalf of providers to resolve issues and close payment loops.
Partnership with Google Cloud: Leveraging Gemini LLM to accelerate innovation while maintaining control of data and outcomes.
Expansion of proprietary data: Enhanced data advantage with financial and clinical data from 1/3 of U.S. hospital discharges annually.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company faces potential risks from the broader economic environment, including patient utilization trends and reimbursement rate pressures that may impact clients, although the diversity of the client base provides some insulation.
Competitive Pressures: Waystar operates in a competitive market with new AI entrants offering lightweight tools. Maintaining its leadership position requires continuous innovation and leveraging its proprietary data and platform advantages.
Regulatory Hurdles: No explicit regulatory risks were mentioned in the transcript.
Supply Chain Disruptions: No explicit supply chain risks were mentioned in the transcript.
Economic Uncertainties: Economic uncertainties could indirectly affect the company through its clients, particularly in healthcare utilization and reimbursement rates.
Strategic Execution Risks: The integration of Iodine Software, while ahead of schedule, carries risks related to achieving the expected cost synergies and cross-sell opportunities. Additionally, the successful deployment of new AI capabilities and maintaining client trust in these innovations are critical to sustaining growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Waystar expects revenue for 2026 to be in the range of $1.274 billion to $1.294 billion, representing 17% year-over-year growth. Normalized organic growth is projected at approximately 10%, with a similar growth rate for Iodine.
Sequential Revenue Growth: Revenue is expected to grow 1% to 3% sequentially throughout 2026, with the third quarter at the low end due to seasonality of patient payments.
Adjusted EBITDA: Adjusted EBITDA is projected to be between $530 million and $540 million, representing 16% year-over-year growth and a margin of approximately 42% for 2026.
Cost Synergies from Iodine Acquisition: Waystar expects to realize approximately $14 million of savings in 2026, which is over 90% of the committed $15 million in cost synergies from the Iodine acquisition.
Long-term Revenue Growth Outlook: Waystar maintains confidence in a normalized low double-digit revenue growth profile for 2026 and beyond.
Market Demand and Innovation: Waystar plans to launch several new AI agents in 2026, advancing its autonomous revenue cycle vision and leveraging its integrated platform for innovation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the appetite of customers to use LLMs and build on their own versus buying from Waystar?
A:The vast majority of clients prefer to integrate AI capabilities into their systems of record or action rather than building their own. Most provider organizations lack the engineering talent to test and deploy AI, and it is not their core competency. Waystar is well-positioned to deliver AI in a cybersecure and interoperable environment.
Q:How does Waystar view the launch of new AI agents in terms of revenue opportunities?
A:The launch of new AI agents is seen as both incremental revenue opportunities and a way to increase the moat of their current AI offerings. Some agents will be new SKUs with new pricing, while others will add incremental automation to existing modules. AI also drives retention, allows for annual price increases, and introduces new SKUs for monetization.
Q:How should the fourth quarter margin be modeled considering the step-up in G&A, R&D, and D&A costs?
A:The step-up includes the additional cost of one full quarter of Iodine. For 2026, gross margins are expected to remain in the high 60s, with EBITDA at 42%, including a 1% benefit from cost synergies. The company is focused on reinvesting for long-term revenue and growth expansion.
Q:Are customers leaning towards point solutions or full end-to-end modernization within RCM?
A:Customers are showing a preference for a platform approach rather than point solutions. AI is embedded in conversations, and the platform approach is displacing multiple vendors and point solutions. Recent bookings indicate strong interest in the platform approach.
Q:What is the expected growth rate for Iodine in 2026?
A:Iodine is expected to grow at a similar rate to Waystar's normalized organic growth rate of 10% for 2026.
Q:How does Waystar view the adoption of AI in healthcare compared to other industries?
A:Waystar sees healthcare as slower to adopt new technology solutions compared to the macro AI market. However, they believe AI is a significant opportunity and are leveraging their relationship with Google's LLM to deliver production-grade, secure, and scalable AI solutions.
Q:What are the assumptions around healthcare utilization by patients in 2026?
A:Healthcare utilization is expected to remain healthy and on the higher side of the historical 1%-2% baseline. This aligns with trends observed in the fourth quarter and is expected to drive growth in both patient payments and provider solutions.
Q:What trends were observed in patient deductible timelines and their impact on volumes?
A:There was a sequential decrease in patient volumes from Q3 to Q4 as patients hit their deductibles. However, this was offset by increased volumes in provider solutions. The impact of high-deductible health plans is expected to be less notable in 2026 due to changes in revenue mix.
Q:Does the rise of AI-related products make customers hesitant to spend or accelerate total spend?
A:AI-related products do not make customers hesitant to spend. Instead, they prioritize efficiency, cost reduction, and cybersecurity. AI is embedded in conversations, and customers are willing to embrace AI as part of a platform approach, driving record bookings and a strong pipeline.
Q:How does Waystar's ROI compare to competitors in the AI space?
A:Waystar has a robust ROI calculator and emphasizes the compounding benefits of using their platform. They report strong win rates, with improvement above their 80% win rate, indicating that their ROI is compelling compared to competitors.
Q:What is Waystar's approach to risk-based contracts and novel contracting?
A:Waystar is exploring performance-based pricing opportunities as they work towards delivering the perfect undeniable claim. They are focused on pricing to the value delivered to clients.
Q:How does Waystar view competition from EHR vendors building AI capabilities?
A:Waystar believes that building a clearinghouse requires a different set of capabilities than developing an EHR system. They focus on being highly interoperable and deeply deployed with EHR systems, which they see as a winning approach.
Q:Do clients use multiple vendors for AI functionality, and how does Waystar address this?
A:Healthcare often has a heterogeneous deployment of technology, and clients may use multiple vendors. However, Waystar emphasizes its deeply deployed network, rich real-time data, and subject matter expertise to address mission-critical problems in revenue cycle management.
Q:How does Waystar ensure its R&D investments stay ahead in the AI space?
A:Waystar invests in innovation, uses LLM tools for productivity gains, and delivers hundreds of feature improvements quarterly. They also scan the market for start-ups with novel AI capabilities to integrate into their platform.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the competitive ROI of other platforms compared to Waystar's ROI. They also did not provide specific details on how they plan to implement performance-based pricing or risk-based contracts, only stating that they are exploring these opportunities.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI cycle
AI workflow
Iodine
Waystar client
action
advantage
agent
billion
booking
care cycle
connectivity
control
core
customer
cybersecure platform
cycle authorization
cycle automation
cycle workflow
decade
denial payment
depth
distribution domain
documentation
domain expertise
durability model
era health
generation
hospital discharge
intervention
issue
learning
logic
loop payment
mission infrastructure
network
pillar
platform value
scale
strength
transaction
trust provider
visibility
WAY Transcript
Waystar Holding Corp. (WAY) Q4 2025 Earnings Call Transcript
Positive2-17
Waystar's earnings call highlights strong revenue and EBITDA guidance, cost synergies from Iodine acquisition, and strategic AI advancements. The Q&A section reveals positive analyst sentiment, with interest in AI-driven growth and platform adoption. Despite unclear responses on competitive ROI and pricing strategies, the overall sentiment remains positive due to raised guidance, AI opportunities, and platform preference. The lack of market cap data suggests a moderate positive reaction, aligning with the 'Positive' category (2% to 8%).
Waystar Holding Corp. (WAY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Waystar Holding Corp. (WAY) Presents at Barclays 23rd Annual Global Technology Conference Transcript
Neutral12-10
Waystar Holding Corp. (WAY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
WAY Slides
WAY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
